Patents by Inventor Tao Pei

Tao Pei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210267513
    Abstract: Disclosed is a method for analyzing dynamic characteristics of EEG functional connectivity related to driving fatigue including: using independent component analysis and wavelet packet transformation to preprocess EEG data; constructing the preprocessed EEG data into a temporal brain network with dynamic characteristics based on a sliding window method; measuring a spatiotemporal topology of the temporal brain network based on a temporal efficiency analysis framework; and performing statistical analysis on the spatiotemporal topology of the temporal brain network to obtain a correlation between behaviors related to driving fatigue and dynamic characteristics of the temporal brain network.
    Type: Application
    Filed: October 8, 2019
    Publication date: September 2, 2021
    Inventors: Hongtao Wang, Xucheng LIU, Ting Li, Cong TANG, Zi'an PEI, Hongwei YUE, Peng CHEN, Tao Xu
  • Patent number: 11078227
    Abstract: Described are 5?-cyclo-phosphonate modified nucleotides, and oligonucleotides, such as interference (RNAi) agents, containing 5?-cyclo-phosphonate modified nucleotides. The RNAi agents having either double-stranded or single-stranded oligonucleotides described herein comprising 5?cyclo-phosphonate modified nucleotides are useful in modulating gene expression as well as therapeutic, diagnostic, target validation, and genomic discovery applications. The RNAi agents and single-stranded antisense oligonucleotides comprising 5?-cyclo-phosphonate modified nucleotides are useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: August 3, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Tao Pei, Michael Lawler
  • Publication number: 20210189394
    Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 24, 2021
    Inventors: David B Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
  • Publication number: 20210100829
    Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
    Type: Application
    Filed: August 11, 2020
    Publication date: April 8, 2021
    Applicant: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
  • Publication number: 20200299691
    Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.
    Type: Application
    Filed: January 31, 2020
    Publication date: September 24, 2020
    Inventors: Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
  • Publication number: 20200299690
    Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.
    Type: Application
    Filed: January 31, 2020
    Publication date: September 24, 2020
    Inventors: Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
  • Patent number: 10780108
    Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: September 22, 2020
    Assignee: ARROWHEAD PHARMACEUTICALS, INC.
    Inventors: Zhen Li, Rui Zhu, Christine Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
  • Publication number: 20200283777
    Abstract: Described herein are compositions and methods for inhibition of Asialoglycoprotein receptor 1 (ASGR1) gene expression. RNA interference (RNAi) agents, e.g., double stranded RNAi agents, and RNAi agent-targeting ligand conjugates for inhibiting the expression of anASGR1 gene are described. Pharmaceutical compositions comprising one or more ASGR1 RNAi agents, optionally with one or more additional therapeutics, are also described. The ASGR1 RNAi agents can be used in methods of treatment of various diseases and conditions, such as cardiometabolic diseases related to elevated non-HDL cholesterol (non-HDL-C) levels, elevated LDL cholesterol (LDL-C) levels, elevated total cholesterol levels, and/or elevated triglyceride (TG) levels.
    Type: Application
    Filed: October 16, 2018
    Publication date: September 10, 2020
    Inventors: Zhen Li, Tao Pei, Rui Zhu, Bruce D. Given, Stacey Melquist
  • Publication number: 20200263179
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
  • Publication number: 20200208149
    Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.
    Type: Application
    Filed: September 12, 2019
    Publication date: July 2, 2020
    Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
  • Patent number: 10662427
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: May 26, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
  • Patent number: 10597657
    Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: March 24, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
  • Patent number: 10590416
    Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 17, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
  • Publication number: 20190382763
    Abstract: RNA interference agents for inhibiting the expression of Factor XII (FXII) gene are described. Pharmaceutical compositions comprising one or more FXII RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in Vivo are also described. Delivery of the FXII RNAi agent(s) to liver cells in vivo provides for inhibition of FXII gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
    Type: Application
    Filed: July 29, 2019
    Publication date: December 19, 2019
    Inventors: Zhen Li, Tao Pei, Steven B Kanner, Rui Zhu, Stacey Melquist, Lauren J Almeida
  • Publication number: 20190377890
    Abstract: Techniques are described for pooling data originating from different entities into a data pool managed by a data pool management system for performing accurate and resource-efficient statistical and other data operations by entities. Techniques further include maintaining rule sets that govern access to the data sets of the data pool. The DPMS uses the rule sets to determine whether a particular data set, on which a particular operation is requested to be performed, qualifies as authorized data for the requesting entity. In an embodiment, the DPMS determines, based on one rule set, that the particular data set does not qualify as authorized data for the particular operation. The DPMS further determines that based on another rule set the particular data set does qualify as authorized data for the particular operation. Based on determining that authorizing rule set overrides the non-authorizing rule set, DPMS proceeds to performing the particular operation using the particular data set.
    Type: Application
    Filed: June 6, 2018
    Publication date: December 12, 2019
    Inventors: MICHAEL BAIRD LEAVITT, CHINMAY VIKRAM GANDHI, HONGCHENG MI, YUAN GAO, SHUO YANG, DYLAN TAO-PEI SU, JULIUS QUINOVEVA QUIAOT, JIAN AN, XIAOZHOU FANG, MELISSA BETH STEIN
  • Patent number: 10450565
    Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: October 22, 2019
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
  • Publication number: 20190292547
    Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
    Type: Application
    Filed: August 4, 2017
    Publication date: September 26, 2019
    Inventors: Zhen Li, Rui Zhu, Christine Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
  • Publication number: 20190255091
    Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
    Type: Application
    Filed: February 4, 2019
    Publication date: August 22, 2019
    Applicant: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
  • Publication number: 20190256849
    Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 22, 2019
    Inventors: Zhen Li, Tao Pei, Agnieszka Glebocka, Michael Lawler, Fred Fleitz, Erich Altenhofer, Pankaj Kumar
  • Publication number: 20190248832
    Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 15, 2019
    Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters